Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients
Novartis announced the publication of clinical data from a post-hoc analysis showing significant improvement in physical and social activities at 8 months with Entresto (sacubitril/valsartan) vs previous standard of care among patients with heart failure with reduced ejection fraction (HFrEF). The study findings were published in JAMA Cardiology.
In this secondary analysis of the PARADIGM-HF trial, the effect of Entresto on 10 activities (dressing, showering, climbing a flight of stairs, walking 100 yards, visiting family or friends, jogging, gardening, hobbies, doing household chores, and intimate/sexual relationships) related to physical and social limitations was evaluated in 7,618 study patients using the Kansas City Cardiomyopathy Questionnaire (KCCQ), which measures heath-related quality of life (HRQL) in heart failure patients; higher scores on the KCCQ indicate fewer symptoms.
Results showed that treatment with Entresto significantly improved 7 of 10 types of physical and social activities at 8 months when compared with enalapril, an ACE inhibitor. The most pronounced improvements were seen in the ability to carry out household chores (adjusted change score difference, 2.35; 95% CI, 1.19–3.50; P<0.001) and the ability to conduct intimate/sexual relationships (adjusted change score difference, 2.72; 95% CI, 0.97–4.46; P=0.002);
Study authors stated that the overall improvement seen in physical and social activity with Entresto vs enalapril was equivalent to a difference of 9 years of aging. Moreover, the treatment effects seen from the 8-month visit lasted throughout the study's 3-year follow-up period.
"This analysis shows that treatment with Entresto can reduce limitations in physical and social activities that are important to heart failure patients, helping to preserve their independence, ability to go about their daily lives and maintain personal relationships," said lead author Scott Solomon, MD, from Brigham and Women's Hospital, Harvard Medical School.
Entresto combines sacubitril, a neprilysn inhibitor, and valsartan, an angiotensin II receptor blocker. It is available as 24mg/26mg, 49mg/51mg, 97mg/103mg strength tablets in 60- and 180-count bottles.
For more information (800) 693-9993 or visit Entresto.com.